BIO Comments on FDA Draft Guidance on Grandfathering Policy for Packages and Homogenous Cases of Product Without Product Identifier
January 26, 2018
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Grandfathering Policy for Packages and Homogenous Cases of Product Without a Product Identifier.
BIO and its member companies are committed to meeting the requirements of the Drug Supply Chain Security Act (DSCSA) and ensuring the U.S. drug supply chain is secure, patients are receiving authentic products, and legitimate medications continue to move without unnecessary delays.
The use of the package date for determining whether an un-serialized product would be grandfathered is critical to a smooth transition under DSCSA from un-serialized to serialized inventory. It’s important these products can be sold and distributed until the product has reached its expiration date.
BIO thanks the FDA for listening to stakeholder concerns on the implementation of the grandfathering provisions of the DSCSA. This draft guidance will help ensure legitimate product can move through the supply chain and help negate potential issues as stakeholders begin implementing the serialization requirements.
Download Full Comments Below
2018-01-26 BIO Comments On DSCSA Grandfathering Policy FINAL
One thing that we can all agree on is the need to give our children a fighting chance so they can lead long and productive lives. That is why it is critical to pass the bipartisan Give Kids a Chance Act and ensure the Pediatric Priority Review…
Dear Colleagues, This month marks my one-year anniversary as BIO's CEO. Like most of us in biotech, this post has been a labor of love. At no time in my 25-year career in this industry have I ever witnessed such awe-inspiring science. Today, we…
Re: BIO Comments on Office of Management and Budget (OMB) Statistical Policy Directive No. 8 North American Industry Classification System (NAICS)-Request for Comments on Possible Revisions for 2027 (USBC–2024–0032)Dear Ms. Orvis,The Biotechnology…
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Grandfathering Policy for Packages and Homogenous Cases of Product Without a Product Identifier.
BIO and its member companies are committed to meeting the requirements of the Drug Supply Chain Security Act (DSCSA) and ensuring the U.S. drug supply chain is secure, patients are receiving authentic products, and legitimate medications continue to move without unnecessary delays.
The use of the package date for determining whether an un-serialized product would be grandfathered is critical to a smooth transition under DSCSA from un-serialized to serialized inventory. It’s important these products can be sold and distributed until the product has reached its expiration date.
BIO thanks the FDA for listening to stakeholder concerns on the implementation of the grandfathering provisions of the DSCSA. This draft guidance will help ensure legitimate product can move through the supply chain and help negate potential issues as stakeholders begin implementing the serialization requirements.